Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HR021618
- Development stage
- Phase 2
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HR021618 is an investigational intravenous agent being developed for the management of moderate to severe pain, particularly in the context of postoperative or postsurgical pain following abdominal or orthopedic surgery. The drug is currently undergoing clinical trials to evaluate its efficacy, safety, and optimal dosing for pain management after surgery. It is being developed by Jiangsu Hengrui Medicine and has not yet reached approval status. The precise mechanism of action has not been publicly disclosed as of now, but it is positioned within the pipeline for non-opioid analgesics targeting acute postoperative pain[1][2][4][7].
Beyond the preview
Go deeper on HR021618.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HR021618.